Collegium files BDSI acquisition pro forma; $669M total consideration, $75M annual synergy target

COLLEGIUM PHARMACEUTICAL, INC

Total consideration for BDSI acquisition: $669.4M ($606.4M cash to stockholders at $5.60/share + $63.0M to retire BDSI debt).
Pro forma combined 2021 revenue $443.6M, net income $23.5M after $132.9M in transaction-related adjustments.
Company expects at least $75M in annual run-rate cost synergies within 12 months of closing (headcount reductions and consolidation).
Acquisition financed via a new $650.0M term loan (modification of existing Collegium term loan); BDSI term loan paid at close.
Preliminary purchase price allocation includes $445M in identifiable intangible assets (Belbuca, Symproic, Elyxyb) and $134M in goodwill.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.